Efficacy of danofloxacin 18% injectable solution in the treatment of Escherichia coli diarrhoea in young calves in Europe.
The efficacy of danofloxacin 18% against naturally occurring Escherichia coli diarrhoea was investigated in calves at seven European sites. Treatment commenced on day 0, with either a single subcutaneous injection of danofloxacin 18% (n=267) at 6 mg/kg repeated on day 2 if required, or reference product containing baquiloprim/sulphadimidine (n=37) or gentamicin (n=98) administered as recommended. E. coli was isolated from 90% to 100% of calves pre-treatment, and the prevalence of serotypes K99 and F41 was 8-46% and 46-92%, respectively. In both treatments, the majority of calves (93.2-93.9%) showed clinical improvement and completed the studies. There were significant reductions for both treatments, in severity of clinical signs on days 4 and 10 compared to day 0 (P<0.0001), and between days 4 and 10 (P<0.05), but no significant differences between treatments (P>0.05). Danofloxacin 18% was clinically safe, and as effective as the reference products in the treatment of E. coli diarrhoea in calves.
Sunderland
Simon J
SJ
Pfizer Animal Health Group, Pfizer Ltd., Sandwich, Kent CT13 9NJ, UK. simon_sunderland@sandwich.pfizer.com
Sarasola
P
P
Rowan
T G
TG
Giles
C J
CJ
Smith
D G
DG
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000627:therapeutic use*; D002417:Cattle; D002418:Cattle Diseases / Q000188:drug therapy* / Q000382:microbiology; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology / Q000662:veterinary*; D004927:Escherichia coli Infections / Q000188:drug therapy* / Q000382:microbiology / Q000662:veterinary*; D005060:Europe; D024841:Fluoroquinolones; D012996:Solutions / Q000008:administration & dosage / Q000627:therapeutic use
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D012996:Solutions; C068581:danofloxacin